Nantahala Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Nantahala Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-754,153	Closed	-$25.5M	–	173
2025 Q4	$25.5M	Buy	754,153 +130,871	+21%	+$4.06M	0.84%	27
2025 Q3	$16.1M	Sell	623,282 -328,331	-35%	-$4.3M	0.56%	42
2025 Q2	$7.61M	Buy	951,613 +324,997	+52%	+$2.48M	0.3%	64
2025 Q1	$6.12M	Buy	626,616 +471,177	+303%	+$4.63M	0.24%	61
2024 Q4	$1.96M	Buy	+155,439	New	+$1.97M	0.08%	108

Nantahala Capital Management's RAPT Position: Q1 2026 in Review

Nantahala Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 754,153 shares — an estimated $25.5M sold.

Nantahala Capital Management first reported a position in RAPT in Q4 2024 and held it in 5 quarters. The position peaked at $25.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Nantahala Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Nantahala Capital Management sold 754,153 RAPT Therapeutics shares in Q1 2026, an estimated $25.5M.
Nantahala Capital Management first reported a position in RAPT Therapeutics in Q4 2024 and held it in 5 quarters.
Nantahala Capital Management's RAPT Therapeutics position peaked at $25.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.